• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - surgery
Tag:

surgery

Health

Breathing polluted air before surgery may worsen recovery outcomes

by Chief Editor May 11, 2026
written by Chief Editor

Imagine preparing for a major elective surgery. You’ve fasted, stopped smoking, and managed your blood pressure. But there is one variable you didn’t consider: the air you breathed the week before you entered the operating room. New research is revealing that the invisible pollutants in our atmosphere may be just as critical to surgical success as the skill of the surgeon or the sterility of the theater.

The Invisible Risk: How PM2.5 Impacts the Scalpel

A groundbreaking study published in Acta Anaesthesiologica Scandinavica has shed light on a dangerous correlation: fine particulate matter (PM2.5) exposure in the seven days leading up to surgery significantly increases the odds of postoperative complications.

PM2.5 refers to tiny pollutants with a diameter of 2.5 micrometers or less. Because they are so small, they penetrate deep into the lungs and enter the bloodstream, triggering systemic inflammation. When a patient undergoes surgery, the body is already under immense physiological stress, releasing proinflammatory cytokines and experiencing hemodynamic shifts.

When you combine the inflammatory “storm” of surgery with the pre-existing inflammation caused by polluted air, the result is a dangerous overlap. This synergy increases the likelihood of severe outcomes, including sepsis, pneumonia, surgical wound infections, stroke, and myocardial infarction.

Did you know? In a study of nearly 50,000 patients in Utah’s Wasatch Front, the risk of postoperative complications jumped from 4.8% to 6.2% when air pollution exceeded EPA daily exposure limits in the week before surgery.

Future Trend: The Rise of “Environmental Pre-habilitation”

Traditionally, “pre-hab” involves exercise and nutrition to prepare a patient for surgery. However, we are moving toward a future of environmental pre-habilitation. In this model, a patient’s geographic location and local air quality index (AQI) become part of their clinical profile.

View this post on Instagram about Future Trend, Environmental Pre
From Instagram — related to Future Trend, Environmental Pre

We can expect to see surgeons and anesthesiologists advising high-risk patients—particularly those with existing comorbidities—to take specific precautions during high-pollution episodes. This could include:

  • HEPA Filtration: Using medical-grade air purifiers in the home for 7-14 days prior to an elective procedure.
  • Activity Modification: Avoiding outdoor exertion during wildfire smoke events or winter inversions.
  • Air Quality Monitoring: Integrating real-time AQI alerts into patient portals to warn them of “high-risk” breathing days.

Precision Scheduling Based on Air Quality

One of the most provocative shifts will be in how we schedule elective surgeries. Currently, surgeries are scheduled based on surgeon availability and hospital capacity. In the future, “environmental windows” may play a role.

For a patient with severe COPD or heart disease, a surgeon might postpone a non-urgent procedure by 48 hours if a severe pollution spike is forecasted. By waiting for a “clean air window,” the surgical team could effectively lower the patient’s baseline inflammation, reducing the risk of a costly and dangerous postoperative infection.

Pro Tip for Patients: If you have a scheduled elective surgery, keep an eye on your local air quality apps. If you notice a spike in PM2.5 (such as during wildfire season), discuss with your doctor whether staying indoors or using an air purifier could help optimize your recovery.

Integrating Environmental Data into Surgical Risk Scores

For decades, clinicians have used tools like the ASA Physical Status Classification System to predict surgical risk. The next evolution of these tools will likely include environmental exposure markers.

Health headlines: Breathing polluted air, vaccine confidence and racial gap in stroke deaths | NewsN

By utilizing Bayesian hierarchical modeling—the same method used in the Utah study—hospitals can begin to quantify how much a patient’s zip code contributes to their risk. This allows for personalized care; a patient living in a highly industrial area or a wildfire-prone region may receive more aggressive postoperative monitoring or prophylactic treatments to counteract the inflammatory effects of PM2.5.

This shift moves us away from a “one size fits all” approach to perioperative care and toward a truly precision-medicine model that accounts for the world outside the hospital walls. For more on how environmental factors impact health, explore our guide on the long-term effects of urban pollution.

FAQ: Air Pollution and Surgery

Does air pollution cause surgical complications directly?
While the research shows a strong association, We see viewed as an “exposure marker.” Pollution triggers inflammatory and thrombotic pathways that overlap with the stress of surgery, making the body more susceptible to complications like sepsis or pneumonia.

FAQ: Air Pollution and Surgery
Utah

How long before surgery does air quality matter?
Current data highlights the 7 days prior to surgery as a critical window, though long-term chronic exposure also plays a role in overall patient resilience.

Who is most at risk?
Patients with higher comorbidity burdens (such as those with heart or lung disease) appear to be the most vulnerable to the effects of preoperative pollution.

Can I prevent these risks?
While you cannot control the outdoor air, using HEPA filters and limiting outdoor exposure during high-pollution alerts can reduce your personal intake of fine particulate matter.

Join the Conversation

Do you think surgeons should consider air quality when scheduling operations? Should hospitals provide air purifiers to high-risk patients? Let us know your thoughts in the comments below or subscribe to our newsletter for the latest in medical innovation.

Subscribe for More Insights

May 11, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Emergency trauma surgery outcomes worse for children in low-income nations

by Chief Editor May 8, 2026
written by Chief Editor

The “Small Adult” Fallacy: Why Pediatric Trauma Care Must Evolve

For too long, emergency medical systems have operated under a dangerous assumption: that children are simply smaller versions of adults. However, as recent data reveals, this “one size fits all” approach to trauma care is costing lives, particularly in the world’s most vulnerable regions.

A landmark international study led by the University of Cambridge, published in The Lancet Child & Adolescent Health, has highlighted a staggering disparity in survival rates. Children requiring life-saving emergency surgery for severe abdominal injuries—known as trauma laparotomies—are almost six times more likely to die in poorer countries than in wealthier ones.

“Children are not just small adults,” explains co-lead author Dr. Michael Bath from the University of Cambridge. He emphasizes that children require specialized equipment, distinct expertise, and rapid access to specialist care—elements that are often missing from trauma systems designed primarily for adults.

Did you know? Across the study’s cohort of 237 children across 32 countries, the overall mortality rate within 30 days of surgery was 8%. However, this figure masks the deep inequality between high- and low-development settings.

Closing the Survival Gap: The Double Challenge

Lower-income nations face what researchers describe as a “double challenge.” Not only do these regions often see a higher proportion of children needing emergency surgery due to trauma—including violence and road traffic accidents—but they also have the least access to the critical resources needed to save them.

Closing the Survival Gap: The Double Challenge
Closing the Survival Gap: Double Challenge

The disparity isn’t just about the surgery itself, but the entire “trauma pathway.” According to Professor Timothy Hardcastle of the University of KwaZulu-Natal, the challenges span from the moment an injury occurs to the recovery phase. These include critical delays in reaching a hospital and further delays in getting the patient into the operating theater.

When children finally do reach care, the lack of essential interventions becomes a primary driver of mortality. The research found that children in poorer countries were significantly less likely to receive:

  • Life-saving blood transfusions.
  • CT scans for accurate diagnosis.
  • Medications specifically used to reduce internal bleeding.
  • Surgery performed by a consultant surgeon.

Future Trends: Redesigning Trauma Systems for the Next Generation

To move the needle on pediatric survival, the global health community is shifting toward a model of “child-centric” trauma care. The goal is to stop copying adult systems and start building pathways tailored to the physiological and clinical needs of children.

Prioritizing Pediatric-Specific Infrastructure

The future of emergency care lies in the implementation of age-specific equipment and referral pathways. Because children have different injury patterns and recovery needs, the tools used in the ER and the ICU must be scaled and specialized for pediatric patients.

View this post on Instagram about Prioritizing Pediatric, Specific Infrastructure
From Instagram — related to Prioritizing Pediatric, Specific Infrastructure

This includes not only the hardware but the “software” of healthcare: specialized staff training and the guaranteed presence of senior clinical care during emergency procedures.

Integrating Diagnostic and Support Services

Improving survival will require a systemic push to make CT imaging and blood banks more accessible in low-resource settings. Without the ability to quickly image an abdomen or replace lost blood, even the most skilled surgeon is limited in what they can achieve.

Pro Tip for Health Policy Makers: Focus on the “golden hour.” Reducing the time between injury and the first surgical intervention is the most effective way to lower mortality rates in pediatric trauma.

A Holistic Approach to Recovery

The trend is moving beyond the operating table. True survival means more than just exiting surgery alive; it means recovering function. Experts are now calling for the integration of pediatric rehabilitation into the emergency care chain to ensure that survivors of severe trauma can return to their normal lives.

08.08.2025, “Children’s Emergency, Trauma and Disaster Care in US Health System”

For more insights on global health disparities, explore our Global Health Equity series or read the original study findings at The Lancet Child & Adolescent Health.

Frequently Asked Questions

What is a trauma laparotomy?

A trauma laparotomy is an emergency surgical procedure where the abdomen is opened to examine and repair severe internal injuries, typically caused by blunt force or penetrating trauma.

What is a trauma laparotomy?
Children

Why can’t adult trauma protocols be used for children?

Children have different physical needs, different ways their bodies respond to trauma, and unique recovery requirements. Equipment and dosages designed for adults can be ineffective or dangerous for children.

What are the primary barriers to pediatric survival in poorer countries?

The main barriers include delays in transport, lack of access to diagnostic imaging (like CT scans), shortages of blood for transfusions, and a lack of specialized pediatric surgical expertise.


Join the Conversation: Do you believe global health organizations are doing enough to prioritize pediatric-specific care? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates in medical research.

May 8, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

New imaging agent shows promise for non-invasive endometriosis diagnosis

by Chief Editor April 30, 2026
written by Chief Editor

Recent Imaging Agent Offers Hope for Earlier Endometriosis Diagnosis and Personalized Treatment

A novel molecular imaging agent, 99mTc-maraciclatide, is showing significant promise in revolutionizing the diagnosis and management of endometriosis, a chronic and often debilitating condition affecting millions of women worldwide. Recent Phase 2 trial data, published in The Lancet Obstetrics and Gynaecology, suggests the agent could provide a non-invasive alternative to laparoscopic surgery for detecting endometriosis, particularly the often-overlooked superficial peritoneal endometriosis (SPE).

The Challenge of Diagnosing Endometriosis

Endometriosis occurs when tissue similar to the lining of the uterus grows outside of it, causing inflammation and pain. Diagnosis currently relies heavily on laparoscopic surgery, an invasive procedure with associated risks and costs. SPE, present in approximately 80% of diagnosed cases, is notoriously difficult to identify even with surgery, leading to significant diagnostic delays. These delays can have a profound impact on a patient’s quality of life and fertility.

How 99mTc-maraciclatide Works

99mTc-maraciclatide is a radiotracer that targets αvβ3 integrin, a protein upregulated during angiogenesis – the formation of new blood vessels. Angiogenesis is a key characteristic of endometriosis lesions. By visualizing the uptake of this tracer using SPECT-CT imaging, clinicians can potentially identify endometriosis lesions without the need for surgery. The DETECT study represents the first apply of this agent for visualizing and diagnosing endometriosis.

Key Findings from the DETECT Study

The Phase 2 DETECT study demonstrated a strong correlation between areas where the imaging agent accumulated and the location of endometriosis lesions confirmed by laparoscopy. Specifically, imaging results aligned with surgical findings in 16 out of 19 cases. Importantly, the imaging agent detected endometriosis in 14 of 17 participants who were surgically confirmed to have the disease, including two cases of thoracic endometriosis – a rarer and often more challenging form to diagnose. No false positives were reported.

Notably, the imaging agent was able to detect lesions across all endometriosis subtypes, suggesting broad applicability. The scan was well-tolerated by patients, with high levels of acceptability reported.

Beyond Diagnosis: Monitoring and Treatment Response

The potential of 99mTc-maraciclatide extends beyond initial diagnosis. Researchers believe it could be a valuable tool for monitoring disease progression and assessing treatment response. Currently, it’s difficult to objectively determine whether a treatment is effective, relying largely on subjective reports of pain reduction. This new imaging agent could provide a quantifiable marker of treatment success, accelerating the development of novel therapies.

View this post on Instagram about Fast Track Designation, Director of the Endometriosis
From Instagram — related to Fast Track Designation, Director of the Endometriosis

Dr. Tatjana Gibbons, lead author of the study from the University of Oxford, emphasized the significance of these findings, stating the agent offers “a highly promising diagnostic and monitoring tool, particularly for superficial peritoneal endometriosis, which is the most common and yet the hardest type of endometriosis to identify.”

Fast Track Designation and Future Outlook

The U.S. Food and Drug Administration (FDA) has granted 99mTc-maraciclatide Fast Track Designation, recognizing the urgent need for improved diagnostic tools for endometriosis. Serac Healthcare, the company developing the agent, is preparing to initiate Phase III multi-center international studies later this year. These larger trials will be crucial to validate the Phase 2 findings and pave the way for regulatory submission.

Professor Christian Becker, Co-Director of the Endometriosis CaRe Centre in Oxford, highlighted the potential impact, stating that if Phase III results are positive, the agent “could both reduce diagnostic delays and provide a validated endpoint for the development of new therapeutics.”

The Rise of Molecular Imaging in Women’s Health

The development of 99mTc-maraciclatide represents a broader trend towards the use of molecular imaging in women’s health. Traditional imaging techniques often lack the sensitivity to detect early-stage disease or subtle changes in disease activity. Molecular imaging, which targets specific biological processes, offers the potential for earlier and more accurate diagnoses, leading to more effective and personalized treatment strategies.

New endometriosis research shows promise in diagnosing patients non-invasively

Professor Krina Zondervan, Co-Director of the Endometriosis CaRe Centre, noted that if confirmed in larger studies, imaging with maraciclatide “could transform clinical research and practice and potentially empower the development of treatments for women across the globe.”

FAQ

Q: What is endometriosis?
A: Endometriosis is a condition where tissue similar to the lining of the uterus grows outside of it, causing pain and inflammation.

Q: What is 99mTc-maraciclatide?
A: It’s a novel molecular imaging agent that helps visualize endometriosis lesions without the need for surgery.

Q: Is this imaging agent currently available?
A: No, it is still under development and undergoing Phase III clinical trials.

Q: What is Fast Track Designation?
A: It’s a designation by the FDA that expedites the development and review of drugs for serious conditions.

Q: What is SPECT-CT imaging?
A: SPECT-CT (Single-Photon Emission Computed Tomography-Computed Tomography) is an imaging technique that combines two different types of scans to provide detailed images of the body.

Did you know? Endometriosis can take an average of 7-10 years to diagnose from the onset of symptoms.

Pro Tip: If you suspect you may have endometriosis, it’s key to consult with a healthcare professional for proper evaluation and diagnosis.

Stay informed about the latest advancements in endometriosis research and treatment. Endometriosis UK is a valuable resource for patients and healthcare professionals alike.

Do you have questions about endometriosis or this new imaging agent? Share your thoughts in the comments below!

April 30, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Researchers use light-activated nanozymes to treat aggressive brain tumors

by Chief Editor April 29, 2026
written by Chief Editor

The Future of Neuro-Oncology: How Nanozymes are Redefining Brain Tumor Treatment

For decades, the treatment of malignant brain tumors has been a battle against both the cancer itself and the body’s own defense mechanisms. Conventional therapies—surgery, radiation, and chemotherapy—often hit a wall when facing aggressive tumors like astrocytomas. The challenge isn’t just the tumor’s growth, but its tendency to invade healthy surrounding tissue, making complete surgical removal nearly impossible.

However, a paradigm shift is occurring. Researchers at Empa and the hospital network HOCH Health Ostschweiz are pioneering the use of nanozymes—biocompatible nanomaterials that act as catalysts—to attack cancer cells directly during surgery. This approach represents a broader trend in precision medicine: moving away from systemic treatments toward localized, high-impact interventions.

Did you know? The blood-brain barrier is a protective mechanism that prevents harmful substances in the bloodstream from entering the brain. While it protects us, it also inadvertently blocks many life-saving chemotherapy drugs from reaching brain tumors.

Breaking the Barrier: The Strategic Shift to Localized Delivery

The most significant hurdle in treating astrocytomas is the blood-brain barrier. Because this barrier is so effective, many traditional drugs never reach their target in sufficient concentrations. The future of neuro-oncology lies in “circumventing” this barrier rather than trying to force drugs through it.

View this post on Instagram about The Future of Neuro, Breaking the Barrier
From Instagram — related to The Future of Neuro, Breaking the Barrier

By applying nanomedicine directly on-site during surgery, surgeons can bypass the blood-brain barrier entirely. According to Empa researcher Giacomo Reina, these drugs specifically accumulate in tumor tissue because cancer cells possess a particularly active metabolism. This ensures that the treatment hits the malignancy while sparing the surrounding healthy brain tissue.

The Power of Near-Infrared (IR) Light

One of the most exciting trends in this field is the integration of external triggers to activate medication. Nanozymes can be engineered to remain dormant until they are triggered by near-infrared light. This allows for:

  • Extreme Precision: Doctors can control exactly when and where the medication becomes active.
  • Reduced Toxicity: Because the activation is localized, the overall dosage can be kept to a minimum, significantly reducing systemic side effects.
  • Deep Penetration: Due to their tiny size, these nanomaterials can penetrate several millimeters into the tissue, targeting malignant cells that the surgeon’s scalpel cannot reach.

Beyond Surgery: The Rise of Material-Based Oncology

The development of nanozymes is part of a larger movement toward material-based approaches to cancer. Empa’s oncology initiative, running from 2025 to 2035, highlights a trend toward treating cancer based on the genetic and metabolic fingerprint of the individual patient.

This personalized approach is critical because of the devastating statistics associated with astrocytomas. In seven out of ten cases, the cancer returns after treatment, and the five-year survival rate is currently only about five percent. The goal of future nanomedicine is to prevent these relapses, even in cases where the cancer has become resistant to conventional chemotherapy.

Pro Tip: When researching new cancer therapies, appear for “minimally invasive” and “biocompatible” descriptors. These often indicate a shift toward treatments that aim to reduce recovery time and patient trauma.

Expanding the Horizon: Spinal Cord and Thyroid Tumors

While the current focus is on the brain, the implications of nanozyme technology extend much further. Experts believe this approach has promising potential for treating other tumors of the spinal cord and brain. The integration of advanced 3D imaging—currently being used to analyze thyroid carcinomas—allows for non-destructive analysis of biopsy samples, providing a clearer roadmap for how to apply these nanomedicines.

For more information on the evolution of oncology, explore our guide on the latest in nanomedicine or visit the Empa research portal.

FAQ: Understanding Nanozymes and Brain Tumor Trends

What exactly are nanozymes?

Nanozymes are biocompatible nanomaterials that possess enzyme-like activity. They can activate drug precursors or generate reactive oxygen compounds that specifically damage and destroy tumor cells.

Why are astrocytomas so demanding to treat?

Astrocytomas are aggressively growing tumors that invade healthy brain tissue. Their location behind the blood-brain barrier makes drug delivery difficult, and they have a high relapse rate (70%).

How does near-infrared light help in cancer treatment?

Near-infrared light acts as a “remote control” for certain nanomedicines. It allows doctors to activate the drug only in the specific area where the tumor is located, minimizing damage to healthy cells.

Can this technology help if chemotherapy has failed?

Yes. Researchers hope that because nanozymes use a different mechanism of action than traditional drugs, they could potentially prevent relapses even in tumors that have become resistant to conventional chemotherapy.

Join the Conversation

Do you think localized nanomedicine will eventually replace systemic chemotherapy for brain tumors? We desire to hear your thoughts on the future of medical technology.

Leave a comment below or subscribe to our newsletter for the latest breakthroughs in oncology.

April 29, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

UIC researchers develop anti-cancer therapy inspired by bacteria in tumors

by Chief Editor April 29, 2026
written by Chief Editor

Starving the Tumor: The Rise of Bacterial-Inspired Cancer Therapies

For decades, the war on cancer has largely focused on attacking the cell’s ability to divide. But, a paradigm shift is occurring. Researchers are now looking at how to “starve” cancer by targeting its energy source: the mitochondria.

View this post on Instagram about Starving the Tumor, The Rise of Bacterial
From Instagram — related to Starving the Tumor, The Rise of Bacterial

Recent breakthroughs at the University of Illinois Chicago (UIC) have highlighted a fascinating novel frontier—using the very bacteria that reside within tumors as a blueprint for creating potent anti-cancer peptides.

Did you know? Mitochondria are often called the “powerhouses” of the cell. Given that cancer cells grow aggressively and rapidly, they often alter their mitochondrial activity to fuel this growth, making them a prime target for targeted therapy.

The Bacterial Blueprint: From Auracyanin to aurB

The concept of looking at the tumor microenvironment for clues is not new, but the application is becoming increasingly sophisticated. By using DNA sequencing on tumor samples from breast cancer patients, researchers identified a specific bacterium containing a protein called auracyanin.

Auracyanin is a cupredoxin—a type of copper-containing protein that transports electrons. Inspired by this, scientists developed a peptide drug called aurB that mimics the protein’s function.

Unlike traditional chemotherapy, which can be a “sledgehammer” approach, aurB is designed for precision. It enters the tumor cells’ mitochondria and binds to ATP synthase, the critical machinery responsible for producing ATP (the cell’s primary energy source). By blocking this process, the therapy essentially cuts off the tumor’s fuel supply.

Breaking the p53 Barrier

One of the most significant hurdles in cancer treatment is the variability of genetic mutations. Many previous anti-tumor peptides relied on the function of a gene called p53, a tumor-suppressor gene.

The problem? p53 is mutated in many cancer patients. If the gene is inactive or mutated, the drug simply doesn’t work. This creates a “genetic lottery” where some patients respond to treatment while others do not.

The development of aurB represents a major step forward because it does not depend on the p53 function. This opens the door for treating a much broader range of patients, regardless of their p53 mutation status.

Expert Insight: “We wanted to have an anti-cancer agent that doesn’t use the p53 function,” explains Tohru Yamada, associate professor at UIC and senior author of the study. This shift toward p53-independent pathways is a critical trend in developing more universal cancer treatments.

Synergy and the Future of Combination Therapy

The future of oncology is likely not a single “magic bullet” but a combination of strategic strikes. Preclinical results have shown that aurB is exceptionally powerful when paired with existing treatments.

UIC scientists develop promising therapy for deadly lung condition

In mouse models of hormone therapy-resistant prostate cancer, the combination of aurB and radiation significantly decreased tumor growth without apparent toxicity. Radiation is already a standard for prostate cancer, but adding a mitochondrial-blocking peptide enhances the overall activity, making the tumor significantly smaller.

This suggests a growing trend toward metabolic sensitization—using a drug to weaken the cancer cell’s energy reserves, making it far more vulnerable to radiation or other therapies.

Beyond the Current Horizon: What’s Next?

The success of aurB is likely just the beginning. The researchers believe that the bacterial proteins found in tumors are an untapped goldmine for drug design.

Beyond the Current Horizon: What's Next?
Frequently Asked Questions What Inspired

As we move toward more personalized medicine, the process of sequencing bacteria within a patient’s own tumor to find specific “inspirations” for peptides could develop into a standard part of drug development. The goal is to find more bacterial proteins that can be manipulated to disrupt the specific metabolic weaknesses of different cancer types.

For further reading on how metabolic targeting is evolving, explore our latest guides on targeted oncology and peptide therapeutics.

Frequently Asked Questions

What is a peptide drug?
A peptide is a short chain of amino acids. A peptide drug like aurB mimics a specific part of a bacterial protein to trigger a desired biological response—in this case, shutting down energy production in cancer cells.

How does aurB differ from traditional chemotherapy?
While many chemotherapies target DNA replication or cell division, aurB specifically targets the mitochondria (the energy factory) to starve the cell of ATP, potentially reducing toxicity to healthy cells.

Is this treatment available for humans yet?
The therapy has shown powerful preclinical results in animal models and cell lines. The researchers have patented aurB and are now exploring avenues for human clinical trials.

Which cancers could this potentially treat?
While specifically tested on hormone therapy-resistant prostate cancer, the research began by analyzing breast cancer samples, suggesting a broad potential for various tumor types that rely on mitochondrial energy.

Join the Conversation

Do you feel bio-inspired therapies are the future of cancer treatment? We want to hear your thoughts on the shift toward metabolic targeting.

Exit a comment below or subscribe to our newsletter for the latest updates in biomedical innovation.

April 29, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Late-night eating may amplify the effects of stress on gut health

by Chief Editor April 23, 2026
written by Chief Editor

The Convergence of Stress and Timing: A Recent Era of Gut Health

For years, we have understood that chronic stress is a primary trigger for bowel dysfunction, often manifesting as sudden bouts of diarrhea or frustrating constipation. However, emerging research presented at Digestive Disease Week (DDW) 2026 suggests that the clock may be just as important as the stressor.

View this post on Instagram about Recent, Health
From Instagram — related to Recent, Health

The conversation is shifting from simply what we eat to when we eat. This intersection of timing and tension is creating a “double hit” to our digestive systems, potentially accelerating the decline of gut health in an increasingly high-pressure world.

Did you know? Researchers apply a metric called “allostatic load” to measure cumulative physiological stress. This score considers factors like blood pressure, cholesterol levels, and body mass index (BMI) to determine how much wear and tear stress has placed on the body.

Understanding the ‘Double Hit’ Phenomenon

Recent data highlights a concerning synergy between late-night eating and chronic stress. When the body is already under significant physiological strain, the timing of caloric intake can amplify digestive issues.

Analysis of over 11,000 participants in the National Health and Nutrition Examination Survey revealed a stark trend: individuals with a high allostatic load who consumed more than 25% of their daily calories after 9 p.m. Were 1.7 times more likely to suffer from constipation and diarrhea compared to low-stress individuals who avoided late-night eating.

The Microbiome Connection

The impact extends beyond simple bowel movements. Data from more than 4,000 participants in the American Gut Project indicates that those combining high stress with late-night eating habits were 2.5 times more likely to report bowel problems.

Crucially, these individuals exhibited significantly lower gut microbiome diversity. This suggests that the timing of our meals may magnify the negative impact of stress on our internal bacteria via the gut-brain axis—the complex communication network of hormones, nerves, and bacteria that links our mind and our gut.

Pro Tip: To support your digestive function, try establishing a structured meal routine. Shifting your larger meals to earlier in the day can help align your eating patterns with your body’s natural rhythms.

The Future of Chrononutrition

We are entering the age of “chrononutrition,” the study of how our body’s circadian rhythms influence the way we process food. As we look forward, the focus of digestive wellness is likely to move toward personalized timing schedules.

The REAL Dangers of Late-Night Eating And How It Affects Your Health

Rather than generic dietary advice, future trends suggest a move toward managing the gut-brain axis by aligning nutrient intake with physiological stress levels. By reducing the “double hit” of late-night calories and high stress, individuals may be able to protect their microbiome diversity and improve overall bowel regularity.

As Dr. Harika Dadigiri, a resident physician at New York Medical College, notes, the goal isn’t to eliminate treats entirely, but to be mindful of timing. Small, consistent shifts in when we eat can lead to long-term improvements in how our bodies handle stress.

For more insights on maintaining a healthy system, explore our guides on optimizing gut health and managing stress-related wellness.

Frequently Asked Questions

Does eating late at night always cause bowel problems?
Not necessarily. The research suggests that late-night eating (more than 25% of calories after 9 p.m.) specifically amplifies digestive issues when combined with high levels of chronic stress.

Frequently Asked Questions
Health Recent

What is the gut-brain axis?
It’s a two-way communication system involving nerves, hormones, and gut bacteria that allows the brain and the gastrointestinal system to influence one another.

How does stress affect the gut microbiome?
High stress, especially when paired with poor meal timing, is associated with lower gut microbiome diversity, which can lead to an increase in bowel dysfunction.

Join the Conversation

Do you find your digestion changes during high-stress periods? Have you noticed a difference in how you feel when you eat later in the evening?

Share your experiences in the comments below or subscribe to our newsletter for the latest updates in digestive health science!

April 23, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Minimally invasive PTAB shows promise for patients with complex peripheral arterial disease

by Chief Editor April 23, 2026
written by Chief Editor

The Evolution of PAD Treatment: Moving Beyond Traditional Leg Bypass

For millions of people living with peripheral arterial disease (PAD), the prospect of restoring blood flow to the legs has historically meant a difficult choice: minimally invasive endovascular therapies that may not be sufficient for complex blockages, or high-risk open surgical bypass surgery.

However, a shift is occurring in the landscape of vascular care. The emergence of Percutaneous Transmural Arterial Bypass (PTAB) is redefining how clinicians approach long-segment superficial femoral artery (SFA) and popliteal artery occlusions, offering a middle ground that combines the logic of a surgical bypass with the recovery profile of a minimally invasive procedure.

Did you know? PAD is a global health challenge impacting over 200 million people worldwide. Without effective treatment, reduced blood flow can lead to severe complications, including the risk of limb loss.

Breaking the ‘Runoff’ Barrier in Complex PAD

One of the most significant hurdles in treating advanced PAD has been “distal runoff”—the number of arteries that successfully carry blood to the lower leg, and foot. Traditionally, patients with single-vessel runoff (where only one of the three main arteries is functional) were viewed as high-risk, often leaving them with limited options other than open surgery.

Recent data from the RODEO-PTAB substudy of the DETOUR2 trial has challenged this paradigm. By analyzing three-year data, researchers evaluated whether having only one runoff vessel predicted poorer outcomes after PTAB using the DETOUR System from Endologix LLC.

The Data: Single-Vessel vs. Multi-Vessel Outcomes

The findings suggest that the number of runoff vessels does not significantly hinder the success of PTAB. In a study of 191 evaluable patients, the results were strikingly similar across both groups:

View this post on Instagram about System, Bypass
From Instagram — related to System, Bypass
  • Primary Patency: At three years, patency was 52.1% for single-vessel runoff compared to 59.5% for those with more than one vessel.
  • Target Lesion Revascularization (CD-TLR): Freedom from clinically-driven revascularization at three years was 65.1% for single-vessel runoff versus 67.2% for multi-vessel runoff.
  • Major Adverse Limb Events (MALE): The proportion of patients remaining MALE-free at three years was 59.9% for single-vessel runoff and 65.2% for multi-vessel runoff.

These statistics indicate that PTAB can be a safe and effective alternative even for the most complex patients who were previously considered poor candidates for endovascular intervention.

How the DETOUR System Redefines Revascularization

Unlike traditional angioplasty or stenting, which attempt to clear a blocked artery, the DETOUR System creates an entirely new pathway for blood. By placing stents through the femoral vein, the system establishes a percutaneous, endovascular femoropopliteal bypass.

This approach allows blood to bypass the diseased SFA segment entirely, improving circulation to the leg while avoiding the inpatient costs and periprocedural morbidity associated with open surgery. For patients experiencing debilitating leg pain, cramping, or numbness, this represents a significant leap in quality of life.

“Findings from this study present that patients with single-vessel runoff maintained excellent patency through three years and can safely benefit from this minimally invasive treatment. These results give operators greater confidence to adopt this technology and treat complex patients who might otherwise be referred for open surgical bypass or have limited treatment options.”
— Sameh Sayfo, MD, MBA, FSCAI, Interventional Cardiologist at Baylor Scott & White The Heart Hospital

Pro Tip: If you or a loved one are discussing PAD treatment options, inquire your vascular specialist about “transmural bypass” options. Understanding whether your condition is categorized as TASC C or D can help determine if a minimally invasive bypass is a viable alternative to open surgery.

Future Trends: The Next Frontier in Endovascular Care

As PTAB becomes more integrated into standard care, the focus is shifting toward optimizing long-term success and expanding real-world application. Industry experts are looking toward several key areas of development:

Real-World Evidence and Diverse Patient Profiles

While clinical trials like DETOUR2 provide a controlled baseline, future trends point toward larger, real-world analyses. This will help clinicians understand how PTAB performs across broader, more diverse patient populations with varying comorbidities.

Refining Anticoagulation Protocols

A critical area of ongoing research is the post-procedure anticoagulation regimen. Researchers are currently evaluating whether specific medication protocols can further improve patency rates and reduce the demand for future revascularization.

Reducing Surgical Dependency

The long-term trend is a clear move toward “surgical avoidance.” By proving that complex patients—even those with limited distal runoff—can benefit from PTAB, the medical community is reducing the reliance on invasive open therapies, thereby lowering hospital stay durations and recovery times.

Frequently Asked Questions

What is PTAB?

Percutaneous Transmural Arterial Bypass (PTAB) is a minimally invasive procedure that creates a new blood flow pathway to bypass blocked arteries in the leg, using a system of stents placed via the femoral vein.

What is PTAB?
System Bypass Percutaneous Transmural Arterial Bypass

How does PTAB differ from a traditional surgical bypass?

A traditional bypass requires open surgery to graft a vein or synthetic tube around a blockage. PTAB is endovascular, meaning it is performed through small incisions using catheters, which typically reduces recovery time and surgical risk.

What does “single-vessel runoff” indicate?

Runoff refers to the arteries that carry blood from the main leg arteries down into the foot. Single-vessel runoff means only one of the three primary arteries is open, which historically made the leg harder to treat via minimally invasive means.

Is the DETOUR System available everywhere?

The DETOUR System is currently approved for use within the United States.

Aim for to stay updated on the latest breakthroughs in vascular health and medtech? Subscribe to our newsletter or leave a comment below to share your thoughts on the future of minimally invasive surgery.

April 23, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

New research calls for improved pediatric burn care infrastructure nationwide

by Chief Editor April 21, 2026
written by Chief Editor

The Critical Gap in Pediatric Burn Care

The landscape of burn treatment in the United States is currently an uneven network. While many acute care hospitals provide basic burn services, there is a significant shortage of specialized facilities equipped to handle the unique needs of children.

According to a review paper co-authored by Dr. James C. Jeng, a trauma, burn, and critical care surgeon at UCI Health, the disparity in resources and skill levels across the country creates a precarious situation for pediatric patients.

Currently, fewer than 40 of the 75 American Burn Association (ABA)-verified programs are specifically verified for pediatrics. This gap suggests a future trend where the medical community must prioritize the expansion of pediatric-verified centers to ensure that children receive age-specific, family-centered care.

Did you recognize? Children account for more than 1 in 4 burn cases at the UCI Health Regional Burn Center, highlighting the constant demand for specialized pediatric intervention.

Preparing for the Unthinkable: Mass Casualty Events

Experts are warning that the U.S. Healthcare system is not currently prepared for a mass disaster involving multiple burn casualties. The urgency to reform the burn care network is being driven by several global threats, including climate change and the potential for nuclear or biological disasters.

Preparing for the Unthinkable: Mass Casualty Events
Health Burn Care

To address these vulnerabilities, specialists have convened children’s burn initiatives aimed at improving the understanding of where specialist care is delivered and defining gaps within the emergency care system.

The future of burn care will likely involve a more strategic, coordinated plan of action to ensure that when large-scale events occur, the network can distribute patients to centers with the appropriate resources and expertise without delay.

The Role of Academic Health Systems

Integration with academic health systems is becoming a cornerstone of advanced burn treatment. Facilities like the UCI Health Regional Burn Center—the first of its kind in Orange County—combine clinical care with innovative research.

Exciting New Research on Keto for Pediatric Mental Health

This synergy allows surgeons and researchers to develop new protocols that improve long-term quality of life for patients, moving beyond simple survival toward full functional recovery.

Why “Children Are Not Small Adults”

One of the most critical shifts in burn care is the recognition that pediatric patients require an entirely different approach than adults. As Dr. Syed F. Saquib, Medical Director of the UCI Health Regional Burn Center, notes, burns affect a child’s growth, development, and long-term quality of life in ways they do not affect adults.

Because of these physiological differences, the trend is moving toward highly specialized pediatric burn units that can provide 24-hour complex care tailored to a child’s developing body.

Pro Tip: To prevent the most common pediatric burns, keep hot liquids, soups, and drinks well away from the reach of children, as scalds are the leading cause of injury.

Understanding the Primary Causes of Pediatric Burns

Data from UCI Health reveals a clear pattern in how children are injured, providing a roadmap for future prevention efforts:

View this post on Instagram about Health, Burn
From Instagram — related to Health, Burn
  • Scalds (67%): Caused by hot liquids, bathwater, or drinks.
  • Contact (22%): Resulting from hot surfaces, tools, or appliances.
  • Flame (6%): Caused by open flames or fires.

These statistics underscore the demand for targeted public health campaigns focusing on home safety to reduce the incidence of scalds and contact burns.

Expert Insight: The Importance of Board-Certified Care

The complexity of burn recovery requires a multidisciplinary approach. Surgeons like Dr. James C. Jeng, who is board-certified in both General Surgery and Surgical Critical Care, bring specialized training in shock, trauma, and burn research to the table.

With over 40 years of experience, Dr. Jeng’s function as a professor in the Division of Trauma, Burns, and Surgical Critical Care at the UC Irvine School of Medicine emphasizes the importance of continuing education and fellowship-trained expertise in managing the most complex burn cases.

For more detailed clinical insights, you can explore the research published in The Annals of Surgery Open.

Frequently Asked Questions

What is an ABA-verified burn center?
It’s a facility that has met rigorous standards set by the American Burn Association to provide high-quality, specialized burn care. Some are further verified specifically for pediatric patients.

Why are pediatric burns different from adult burns?
Children’s skin and bodies are developing; burns can impact their growth and long-term development, requiring age-specific and family-centered care.

What is the most common cause of burns in children?
Scalds from hot liquids, bathwater, or drinks are the most common, accounting for approximately 67% of pediatric burn cases at UCI Health.

Join the Conversation

How can we better prepare our communities for burn emergencies? Do you think there is enough awareness regarding pediatric burn prevention?

Share your thoughts in the comments below or subscribe to our newsletter for more health insights!

April 21, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Microbes in the digestive tract help tailor treatment for melanoma patients

by Chief Editor April 20, 2026
written by Chief Editor

The New Frontier of Oncology: Can Your Gut Bacteria Predict Cancer’s Return?

For decades, the fight against melanoma has relied on a standard playbook: surgical removal followed by immunotherapy to prime the immune system. But for 25% to 40% of patients, the cancer finds a way back. The medical community has long struggled with a frustrating question: Why do some patients thrive although others relapse despite receiving the same treatment?

The answer may not be in the tumor itself, but in the trillions of microbes living in our digestive tracts. Recent breakthroughs from researchers at NYU Langone Health suggest that our gut microbiome acts as a biological “forecast,” predicting the likelihood of cancer recurrence with staggering accuracy—up to 94% in some cases.

Did you know? Your gut contains more microbial cells than you have human cells in your entire body. This “forgotten organ” essentially trains your immune system to distinguish between a harmless piece of food and a dangerous pathogen.

Beyond Geography: The Rise of Microbial “Fingerprinting”

One of the biggest hurdles in microbiome research has been the “geography gap.” For years, a bacterial marker that predicted success in a patient in New York might be completely irrelevant for a patient in Sydney. This inconsistency made it nearly impossible to create a universal diagnostic tool.

View this post on Instagram about Instead, Beyond Geography
From Instagram — related to Instead, Beyond Geography

The game-changer is a new approach called microbial fingerprinting. Instead of looking for one specific “magic” bacterium, scientists are now matching patients based on the overall similarity of their gut ecosystems. By grouping patients with similar “fingerprints,” researchers can predict recurrence regardless of where the patient lives.

This shift moves us away from “one-size-fits-all” medicine and toward a model of precision oncology. By analyzing taxa such as Eubacterium and Clostridium, doctors can now identify high-risk patients before they even initiate their first round of immunotherapy.

The Future Trend: Real-Time Microbiome Monitoring

While current research focuses on a single pre-treatment test, the next logical step is longitudinal monitoring. Imagine a world where a simple stool sample every three months allows oncologists to notice if a patient’s microbiome is shifting toward a “high-risk” state, triggering a change in medication before a tumor even appears on a scan.

From Prediction to Prevention: Engineering the Gut

Predicting recurrence is a massive leap forward, but the ultimate goal is modulation. If we know that certain bacterial groups increase the risk of melanoma returning, can we simply “edit” the gut to remove them or add beneficial ones?

We are already seeing the emergence of several potential therapeutic avenues:

  • Next-Gen Probiotics: Moving beyond yogurt to pharmaceutical-grade bacterial strains designed to enhance the efficacy of drugs like nivolumab and ipilimumab.
  • Fecal Microbiota Transplants (FMT): Transferring “healthy” microbiomes from patients who responded well to immunotherapy into those who didn’t.
  • Precision Nutrition: Using AI-driven diets to starve cancer-fueling bacteria while feeding the ones that support T-cell activity.
Pro Tip: While clinical microbiome transplants are for medical use, you can support your own “immune-training” bacteria by consuming a diverse range of prebiotic fibers—found in garlic, onions, leeks and asparagus—which feed the beneficial taxa in your gut.

Scaling the Model: Other Cancers in the Crosshairs

The implications of the NYU Langone study extend far beyond skin cancer. The gut-immune axis is a universal biological system. Experts believe this “fingerprinting” method will soon be applied to other high-risk malignancies, including:

Colorectal Cancer: Where the microbiome is already known to play a direct role in tumor initiation.

Lung Cancer: Investigating how the “gut-lung axis” influences the success of checkpoint inhibitors.

Breast Cancer: Exploring the role of systemic inflammation driven by gut dysbiosis.

By building global databases of microbial fingerprints, the medical community is essentially creating a “Google Maps” for the human microbiome, allowing doctors to navigate a patient’s unique biological terrain to locate the most effective treatment path.

Case Study: The Impact of Personalized Immunotherapy

Consider a hypothetical patient, “Patient X,” who has high-risk melanoma. Under the old system, they receive standard immunotherapy and wait a year for a scan. Under the new paradigm, a pre-treatment microbiome test reveals a “high-risk fingerprint.” Instead of the standard dose, their doctor combines immunotherapy with a targeted prebiotic regimen to shift their microbiome, potentially turning a predicted relapse into a permanent remission.

Frequently Asked Questions

Q: Does this signify I can prevent cancer by taking probiotics?
A: Not exactly. While a healthy gut supports the immune system, these specific findings are about predicting and enhancing the effectiveness of medical treatments like immunotherapy, not replacing them.

Q: How accurate is the microbiome in predicting cancer recurrence?
A: In recent studies using the fingerprinting method, accuracy ranged from 83% to 94%, depending on the geographical region and the similarity of the microbial groups.

Q: Why does geography affect my gut bacteria?
A: Your microbiome is shaped by your diet, environment, local water sources, and genetics—all of which vary significantly between, for example, North America and Eastern Europe.

Q: Is this test available at my local clinic?
A: Most of these findings are currently in the clinical trial and research phase. However, the goal is to integrate these tests into standard oncology care in the coming years.

Join the Conversation

Do you suppose the future of medicine lies in our microbes? Are you interested in how precision nutrition can impact long-term health? Let us know your thoughts in the comments below or subscribe to our newsletter for the latest breakthroughs in oncology and biotechnology.

Subscribe for More Insights

April 20, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Liver cancer burden rising globally amid shift to metabolic risks

by Chief Editor April 15, 2026
written by Chief Editor

The Looming Liver Cancer Crisis: A Global Shift in Risk Factors

Liver cancer remains a significant global health threat, ranking as the third leading cause of cancer-related deaths worldwide. In 2022 alone, nearly 870,000 new cases were reported, with hepatocellular carcinoma accounting for almost 80% of these. A concerning trend is emerging: even as progress has been made in combating virus-related liver cancer, a new driver is accelerating the disease’s spread – metabolic dysfunction-associated steatotic liver disease (MASLD), linked to obesity, diabetes, and poor lifestyle choices.

China at the Epicenter of the Global Burden

China bears a disproportionate share of the global liver cancer burden, accounting for over 40% of cases. This reflects a complex interplay of historical factors, including widespread hepatitis B and C infections, and increasingly, the rise of metabolic risk factors. Researchers, led by Professor Jian Zhou and Dr. Ao Huang at Fudan University’s Liver Cancer Institute, along with collaborators at Massachusetts General Hospital and Harvard Medical School, have conducted a comprehensive analysis of global cancer databases to understand these evolving trends.

View this post on Instagram about Liver, Cancer
From Instagram — related to Liver, Cancer

A Projected Surge in Cases: The Impact of MASLD

Despite slight declines in age-standardized incidence and mortality rates in recent decades, the absolute number of liver cancer cases is projected to rise dramatically. If current trends continue, over 1.5 million cases could occur annually by 2050. This increase is largely attributed to the growing prevalence of MASLD. While hepatitis B vaccination and antiviral therapies have reduced virus-related liver cancer, metabolic risk factors are rapidly becoming dominant.

Understanding MASLD: A Silent Epidemic

MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is a condition where fat accumulates in the liver in individuals who drink little or no alcohol. It’s strongly associated with obesity, type 2 diabetes, and metabolic syndrome. As these conditions become more prevalent globally, so too does the risk of MASLD progressing to more serious liver diseases, including cirrhosis and liver cancer.

Understanding MASLD: A Silent Epidemic
Liver Cancer Global

Disparities in Access to Care: A Global Inequality

The burden of liver cancer is not evenly distributed. Higher incidence and mortality rates are concentrated in low- and middle-income regions, where access to vaccination, screening, and treatment is limited. Men, older adults, and socioeconomically disadvantaged populations are also at higher risk. Environmental factors, such as aflatoxin contamination in food, further exacerbate the problem in certain regions.

Prevention is Key: A 60% Preventability Rate

The research highlights a crucial message: up to 60% of liver cancer cases are preventable. Strategies include vaccination against hepatitis B, lifestyle modifications to address obesity and diabetes, improved food safety to minimize aflatoxin exposure, and early disease management. Public health campaigns promoting healthier diets, increased physical activity, and routine screening for high-risk individuals are essential.

Liver Cancer prevalence rising at astounding rates. Early detection is critical! #cancer #HCC

Pro Tip:

Regular check-ups with your doctor, especially if you have risk factors like obesity, diabetes, or a family history of liver disease, can help detect early signs of liver problems.

The Role of Artificial Intelligence in Transforming Liver Cancer Management

Looking ahead, the integration of artificial intelligence (AI) holds immense promise for transforming liver cancer management. AI can enable personalized risk prediction, earlier diagnosis, and more effective treatment planning. What we have is particularly crucial in resource-limited settings where early detection remains a significant challenge.

The Role of Artificial Intelligence in Transforming Liver Cancer Management
Liver Cancer Global

The Future of Liver Cancer Care: A Collaborative Approach

Addressing the liver cancer crisis requires a coordinated global effort involving public health, oncology, data science, and policy sectors. Integrated strategies that tackle both infectious and metabolic health challenges are essential, particularly in rapidly developing regions. Such collaborations could lead to earlier diagnoses, improved survival rates, and reduced healthcare costs.

Frequently Asked Questions (FAQ)

Q: What is the main cause of liver cancer?
A: While hepatitis B and C were historically major causes, metabolic dysfunction-associated steatotic liver disease (MASLD) is now a leading driver.

Q: Is liver cancer preventable?
A: Yes, up to 60% of cases are preventable through vaccination, lifestyle changes, and early detection.

Q: What are the symptoms of liver cancer?
A: Symptoms can be vague and often appear in later stages, including abdominal pain, weight loss, and jaundice. Early detection through screening is crucial.

Q: How is AI being used in liver cancer diagnosis?
A: AI is being developed to analyze medical images and data to identify early signs of liver cancer and predict individual risk.

Q: Where can I find more information about liver cancer?
A: You can find more information at The National Cancer Institute.

What are your thoughts on the rising rates of liver cancer? Share your comments below and let’s start a conversation about prevention and early detection!

April 15, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • Public health forum calls for preparedness amid rising hantavirus concerns

    May 11, 2026
  • Huge black holes form in mergers, study says

    May 11, 2026
  • Daugavpils Social Service Expands Support and Enhances Service Quality in 2025

    May 11, 2026
  • EU Prepares New Sanctions Targeting Russian Oil Fleet

    May 11, 2026
  • EU Imposes Sanctions on Violent Israeli Settlers and Hamas Leaders

    May 11, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World